Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups
In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fa...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Pharmacists Association 2023-01, Vol.63 (1), p.424-429 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 1 |
| container_start_page | 424 |
| container_title | Journal of the American Pharmacists Association |
| container_volume | 63 |
| creator | Abdul-Mutakabbir, Jacinda C. Tillman, Frank Marcelin, Jasmine R. Saunders, Ila M. Arya, Vibhuti |
| description | In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities. |
| doi_str_mv | 10.1016/j.japh.2022.10.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9625842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1544319122003740</els_id><sourcerecordid>2747278074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-c26270107d75ee1dd8595c2a691b3cceb31da61fb76fd9a022618cda8f7a01ce3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEoqXwAiyQl2wytZ0fJwghVcNfpUpdMLC1PPZN5o4SO7WdQcOr8LI4mraCDSsfXX_n2Lony14zumKU1Zf71V5NuxWnnKfBivLqSXbOqrLMi7KiTx80a9lZ9iKEPaVc1G3zPDsr6lJQUbDz7Pe3wf0EQybveg8hoLPvyGYHZI44YDwS15ENhEiiIxsPKhK0GFFFPEBImuCYrAe0PYnJZaEfQMcUiBbu5kQmKkWsb39cf8xZS9ToEuqVRjUMx0uIO4t6kWRE63wy_Erm3rt5Ci-zZ50aAry6Py-y758_bdZf85vbL9frq5tcl1UVc81rLiijwogKgBnTVG2luapbti20hm3BjKpZtxV1Z1qVtlWzRhvVdEJRpqG4yD6ccqd5O4LRYKNXg5w8jsofpVMo_72xuJO9O8i25lVT8hTw9j7Au7s5bUuOGDQMg7Lg5iC5KAUXDRVlQvkJ1d6F4KF7fIZRubQq93JpVS6tLrPUajK9-fuDj5aHGhPw_gRAWtMBwcugEawGgz7VIY3D_-X_AbAsuHk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2747278074</pqid></control><display><type>article</type><title>Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Abdul-Mutakabbir, Jacinda C. ; Tillman, Frank ; Marcelin, Jasmine R. ; Saunders, Ila M. ; Arya, Vibhuti</creator><creatorcontrib>Abdul-Mutakabbir, Jacinda C. ; Tillman, Frank ; Marcelin, Jasmine R. ; Saunders, Ila M. ; Arya, Vibhuti</creatorcontrib><description>In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities.</description><identifier>ISSN: 1544-3191</identifier><identifier>EISSN: 1544-3450</identifier><identifier>DOI: 10.1016/j.japh.2022.10.025</identifier><identifier>PMID: 36470731</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>COVID-19 ; Humans ; Pandemics ; Social Group ; United States - epidemiology ; Vaccination</subject><ispartof>Journal of the American Pharmacists Association, 2023-01, Vol.63 (1), p.424-429</ispartof><rights>2022 American Pharmacists Association</rights><rights>Copyright © 2022 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-c26270107d75ee1dd8595c2a691b3cceb31da61fb76fd9a022618cda8f7a01ce3</citedby><cites>FETCH-LOGICAL-c455t-c26270107d75ee1dd8595c2a691b3cceb31da61fb76fd9a022618cda8f7a01ce3</cites><orcidid>0000-0002-8805-3734 ; 0000-0003-4162-6408</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,27928,27929</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36470731$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdul-Mutakabbir, Jacinda C.</creatorcontrib><creatorcontrib>Tillman, Frank</creatorcontrib><creatorcontrib>Marcelin, Jasmine R.</creatorcontrib><creatorcontrib>Saunders, Ila M.</creatorcontrib><creatorcontrib>Arya, Vibhuti</creatorcontrib><title>Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups</title><title>Journal of the American Pharmacists Association</title><addtitle>J Am Pharm Assoc (2003)</addtitle><description>In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities.</description><subject>COVID-19</subject><subject>Humans</subject><subject>Pandemics</subject><subject>Social Group</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><issn>1544-3191</issn><issn>1544-3450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEoqXwAiyQl2wytZ0fJwghVcNfpUpdMLC1PPZN5o4SO7WdQcOr8LI4mraCDSsfXX_n2Lony14zumKU1Zf71V5NuxWnnKfBivLqSXbOqrLMi7KiTx80a9lZ9iKEPaVc1G3zPDsr6lJQUbDz7Pe3wf0EQybveg8hoLPvyGYHZI44YDwS15ENhEiiIxsPKhK0GFFFPEBImuCYrAe0PYnJZaEfQMcUiBbu5kQmKkWsb39cf8xZS9ToEuqVRjUMx0uIO4t6kWRE63wy_Erm3rt5Ci-zZ50aAry6Py-y758_bdZf85vbL9frq5tcl1UVc81rLiijwogKgBnTVG2luapbti20hm3BjKpZtxV1Z1qVtlWzRhvVdEJRpqG4yD6ccqd5O4LRYKNXg5w8jsofpVMo_72xuJO9O8i25lVT8hTw9j7Au7s5bUuOGDQMg7Lg5iC5KAUXDRVlQvkJ1d6F4KF7fIZRubQq93JpVS6tLrPUajK9-fuDj5aHGhPw_gRAWtMBwcugEawGgz7VIY3D_-X_AbAsuHk</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Abdul-Mutakabbir, Jacinda C.</creator><creator>Tillman, Frank</creator><creator>Marcelin, Jasmine R.</creator><creator>Saunders, Ila M.</creator><creator>Arya, Vibhuti</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8805-3734</orcidid><orcidid>https://orcid.org/0000-0003-4162-6408</orcidid></search><sort><creationdate>20230101</creationdate><title>Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups</title><author>Abdul-Mutakabbir, Jacinda C. ; Tillman, Frank ; Marcelin, Jasmine R. ; Saunders, Ila M. ; Arya, Vibhuti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-c26270107d75ee1dd8595c2a691b3cceb31da61fb76fd9a022618cda8f7a01ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>COVID-19</topic><topic>Humans</topic><topic>Pandemics</topic><topic>Social Group</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdul-Mutakabbir, Jacinda C.</creatorcontrib><creatorcontrib>Tillman, Frank</creatorcontrib><creatorcontrib>Marcelin, Jasmine R.</creatorcontrib><creatorcontrib>Saunders, Ila M.</creatorcontrib><creatorcontrib>Arya, Vibhuti</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of the American Pharmacists Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdul-Mutakabbir, Jacinda C.</au><au>Tillman, Frank</au><au>Marcelin, Jasmine R.</au><au>Saunders, Ila M.</au><au>Arya, Vibhuti</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups</atitle><jtitle>Journal of the American Pharmacists Association</jtitle><addtitle>J Am Pharm Assoc (2003)</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>63</volume><issue>1</issue><spage>424</spage><epage>429</epage><pages>424-429</pages><issn>1544-3191</issn><eissn>1544-3450</eissn><abstract>In the United States, coronavirus disease 2019 (COVID-19) has resulted in more than 95 million infections and 1 million deaths (as of September 2022), with individuals of racially/ethnically minoritized groups being disproportionately represented among these numbers. Despite the apparent pandemic fatigue in many communities, systemic and structural racism continue to place racially/ethnically minoritized groups at a disadvantage for overcoming the virus, especially as it relates to receiving vaccinations and COVID-19 targeted therapeutics. Test to Treat programs have the potential to mitigate these disparities by rapidly identifying the presence of a COVID-19 infection and readily offering treatment options. Nonetheless, Test to Treat programs must be optimized to adequately address the limitations to care within racially/ethnically minoritized communities.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36470731</pmid><doi>10.1016/j.japh.2022.10.025</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-8805-3734</orcidid><orcidid>https://orcid.org/0000-0003-4162-6408</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1544-3191 |
| ispartof | Journal of the American Pharmacists Association, 2023-01, Vol.63 (1), p.424-429 |
| issn | 1544-3191 1544-3450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9625842 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | COVID-19 Humans Pandemics Social Group United States - epidemiology Vaccination |
| title | Slowed progression: The utility of Test to Treat initiatives in improving the neglected inequities of COVID-19 among racially/ethnically minoritized groups |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T04%3A46%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Slowed%20progression:%20The%20utility%20of%20Test%20to%20Treat%20initiatives%20in%20improving%20the%20neglected%20inequities%20of%20COVID-19%20among%20racially/ethnically%20minoritized%20groups&rft.jtitle=Journal%20of%20the%20American%20Pharmacists%20Association&rft.au=Abdul-Mutakabbir,%20Jacinda%20C.&rft.date=2023-01-01&rft.volume=63&rft.issue=1&rft.spage=424&rft.epage=429&rft.pages=424-429&rft.issn=1544-3191&rft.eissn=1544-3450&rft_id=info:doi/10.1016/j.japh.2022.10.025&rft_dat=%3Cproquest_pubme%3E2747278074%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2747278074&rft_id=info:pmid/36470731&rft_els_id=S1544319122003740&rfr_iscdi=true |